Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $32.81 million versus the consensus estimate of $36.61 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.